Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Adamantane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adamantane SCHEMBL8402827 | 1.00 | FFAR3 (0.54) | FFAR3LCKFYNHSD11B1TSHR | |
| Adamantane SCHEMBL28005909 | 0.88 | LMNA (0.50) | FFAR3LCKFYNHSD11B1TSHR | |
| Acetic Acid SCHEMBL14244268 | 0.86 | FFAR3 (0.47) | FFAR3LCKFYNHSD11B1TSHR | |
| Adamantane SCHEMBL7710713 | 0.85 | CHRNB2 (0.39) | HSD11B1TSHRCHRNB2CHRNB4CHRNA3 | |
| Adamantane SCHEMBL974954 | 0.84 | HSD11B1 (0.48) | HSD11B1TSHRCYP2C9LMNACYP2D6 | |
| Adamantane SCHEMBL3981833 | 0.84 | HSD11B1 (0.48) | HSD11B1TSHRCYP2C9LMNACYP2D6 | |
| Adamantane SCHEMBL935449 | 0.84 | HSD11B1 (0.48) | HSD11B1TSHRCYP2C9LMNACYP2D6 | |
| Adamantane SCHEMBL14841654 | 0.81 | LMNA (0.57) | HSD11B1TSHRCHRNB2CHRNB4CHRNA3 | |
| Adamantane SCHEMBL10365099 | 0.81 | CHRNB2 (0.37) | HSD11B1TSHRCHRNB2CHRNB4CHRNA3 | |
| Adamantane SCHEMBL131439 | 0.81 | TDP1 (0.38) | FFAR3LCKFYNHSD11B1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14251 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823115-B | Compound for degrading Pol theta based on hydrophobic tag and preparation method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| WO-2026090085-A1 | TREATMENT OF CD33 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12565653-B2 | ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | claimed |
| US-12534731-B2 | Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | claimed |
| EP-4627082-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250283079-A1 | ACTIN-BINDING LIM PROTEIN 3 (ABLIM3) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-09-11 | — | — | US | claimed |
| US-12391945-B2 | Coronavirus IRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-08-19 | — | — | US | claimed |
| EP-4594492-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| US-12378553-B2 | Modified double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | claimed |
| US-20020039741-A1 | Antitumor agent | DEAN NICHOLAS M (US) | 2002-04-04 | — | — | US | claimed |
| EP-0957926-A4 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS INC (US) | 2002-01-23 | — | — | EP | claimed |
| US-6319906-B1 | FOR THERAPY OF AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, FOR INHIBITING ALLOGRAFT REJECTION | ISIS PHARMACEUTICALS | 2001-11-20 | — | — | US | claimed |
| US-6312900-B1 | FOR MODULATING METASTASIS OF MALIGNANT TUMORS VIA MODULATION OF ACTIVATING PROTEIN 1 | ISIS PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | claimed |
| JP-2000507833-A | — | — | 2000-06-27 | — | — | JP | claimed |
| US-6077833-A | FOR DIAGNOSIS, PREVENTION AND TREATMENT OF IMMUNE STATES AND DISORDERS AMENABLE TO TREATMENT THROUGH MODULATION OF T CELL ACTIVATION SUCH AS FOR PREVENTING ALLOGRAFT REJECTION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-20 | — | — | US | claimed |
| US-6001991-A | NUCLEOTIDE SEQUENCES WHICH HYBRIDIZE TO AND SUPPRESS EXPRESSION OF MULTIDRUG RESISTANCE GENE; FOR PREVENTING OR MODULATING THE DEVELOPMENT OF MULTIDRUG RESISTANCE DURING CHEMOTHERAPEUTIC TREATMENT OR RESENSITIZING TREATED CELLS | ISIS PHARMACEUTICALS INC. (US) | 1999-12-14 | — | — | US | claimed |
| EP-0957926-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1998029124-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| WO-1998014615-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF MDR P-GLYCOPROTEIN GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1998-04-09 | — | — | WO | claimed |